Labs
Order diagnostics on your own lab account.
You hold the lab contract and the lab's API key. neolife relays the order, produces the paperwork the draw needs, tracks the specimen, and carries the result back to a licensed clinician — then stops. Nothing on a lab order is metered, and that is a legal constraint rather than a pricing decision.
What connects
The order, the draw, and the result.
A lab order is not finished when it is placed — a sample still has to come out of a patient, travel, get accessioned, and come back to somebody licensed to act on it. Each of those steps is a state you can read, including the ones that mean nothing arrived.
Four collection modalities
Chosen per order, because it changes the patient's day.
A patient service centre draw, an at-home phlebotomist visit, a self-collection kit shipped to the patient and returned, or a draw by your own staff in clinic. Every modality produces a requisition — the document that authorises the lab to run the panel — plus specimen labels wherever the sample is handled outside the lab's own site, and an ABN where one is required. Those come out as PDFs; they are not something you assemble from an API response.
A lifecycle that names failure
A stalled order is visibly stalled, not silently absent.
The order walks a fixed set of states from requisition through scheduled, collected, in transit, at the lab, and resulted. Two of them are the reason this list is worth reading: a failed collection is its own state, because a patient who never went to the draw site and a specimen that was rejected both look identical from outside as “no result” and both need a human; and partial results are distinct from complete ones, because a panel with one analyte still running is not a panel that came back.
The release gate
Resulted is not reviewed.
A result returned by the lab is not visible to the patient until a licensed clinician has reviewed and released it. That permission sits in the clinical set alongside order approval and intake review — it follows the licence, not seniority, so an administrator cannot hold it and no configuration grants it to one. A critical value flagged by the lab escalates immediately as an exception rather than waiting in the review queue, because a critical result sitting behind a release gate until someone happens to open the console is the exact failure the gate exists to prevent.
Results into the chart
Write-back is triple-gated on purpose.
With a connected EMR, a reviewed result summary can be written back into the chart as a task, a non-visit note, or a FHIR DiagnosticReport. That path needs lab ordering, EMR integration, and its own third switch, because it is the one place where lab PHI crosses into a third-party system — turning on lab ordering must not, as a side effect, start pushing results into a chart. Where the chart cannot accept the write, the result is held in neolife and the provider is notified.
The boundary
What neolife never does with a result.
neolife never interprets a result, never derives a verdict from one, and never releases one to a patient on its own. The rail carries the result to a clinician and stops there. Every reading, every judgement, and every release is a licensed act performed by a licensed person.
What patients do get directly is their own logistics. A patient can see what was ordered and where it stands, and can book or rebook their own draw — which is a phone call your staff does not take, without moving a single clinical decision outside the licence.
How the money works
Nothing. Not a per-panel fee, not a percentage, not a rebate.
You sign with the lab, you agree the panel prices, you get the client id, and neolife never appears in that agreement. The lab invoices you directly at your negotiated rate. Your flat neolife platform fee is the same whether you order one panel a month or a thousand.
Nothing on a lab order is metered — and the accurate word is absent rather than zero-rated. The lab path writes no usage event at all, so there is no dormant counter that a later configuration change could start billing from. An unbuildable shape beats a disabled one.
There is no percentage-margin field anywhere in the platform, in this category or any other. Not disabled, not gated behind an approval: absent. A percent-of-cost markup on a clinical service tracks the value of the clinical act, so a basic panel and a comprehensive one would earn wildly different amounts for identical work on our side. That is income that rises with how much medicine gets ordered.
Hard stop — no approval lifts this
For labs, the managed billing mode is prohibited, not merely locked.
EKRA — the Eliminating Kickbacks in Recovery Act, 18 U.S.C. §220 — makes it an offence to pay or receive remuneration in exchange for referring a patient to a laboratory, and unlike the Anti-Kickback Statute it is all-payor: there is no carve-out for cash-pay business, so a cash-pay posture buys no relief for a cash-pay clinic or for a cash-pay platform. A margin on a lab transaction is remuneration that scales with lab referrals, which is the shape the statute describes. So a lab connection in managed mode is refused for every approval state, including one with a fair-market-value basis and a counsel memo already on file — the refusal is checked before the approval gates, because counsel clearance cannot change what the shape is. This is a description of how the product behaves, not legal advice; your own obligations depend on your structure, your payor mix, and your states.
Bring the lab account you already have. Keep the invoice you already negotiated.
One API for the order, the requisition, the specimen, and the clinician review — and $0 of it flows to us.
Product names and logos are the trademarks of their respective owners and are used here only to identify the systems NeoLife interoperates with. Their use does not imply affiliation with, sponsorship by, or endorsement from those companies.